Roche Holding AG Income Taxes 2010-2023 | RHHBY

Roche Holding AG income taxes from 2010 to 2023. Income taxes can be defined as the total amount of income tax expense for the given period.
Roche Holding AG Annual Income Taxes
(Millions of US $)
2023 $1,917
2022 $2,930
2021 $2,695
2020 $3,090
2019 $2,522
2018 $3,357
2017 $3,479
2016 $3,324
2015 $3,050
2014 $3,261
2013 $3,567
2012 $2,721
2011 $2,651
2010 $2,230
2009 $1,590
Roche Holding AG Quarterly Income Taxes
(Millions of US $)
2023-12-31
2023-06-30
2022-12-31
2022-06-30
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $713.355B 118.79
Novo Nordisk (NVO) Denmark $556.005B 45.80
Johnson & Johnson (JNJ) United States $355.660B 14.15
Merck (MRK) United States $319.643B 84.13
AbbVie (ABBV) United States $286.261B 14.55
AstraZeneca (AZN) United Kingdom $213.091B 18.88
Novartis AG (NVS) Switzerland $200.111B 13.86
Pfizer (PFE) United States $146.716B 14.16
Sanofi (SNY) $116.969B 10.53
Innoviva (INVA) United States $0.910B 6.43